
Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 463 - 463
Published: April 2, 2025
Background: Cannabidiol (CBD) is a natural compound from the Cannabis sativa L. plant, which has anti-inflammatory, anti-nociceptive, neuroprotective, and antibacterial activities. Objective: The aim of this study was to develop sustained-release device CBD that can provide an effect against Gram-positive bacteria Streptococcus mutans Staphylococcus aureus for extended periods time. Methods: incorporated into biodegradable PURASORB 5010 or 7510 DL-lactide/glycolide polymers using either dimethylsulfoxide (DMSO) acetone as solvent, dried polymer scaffolds were exposed daily fresh culture bacteria. bacterial growth determined by optical density, metabolic activity biofilms MTT assay. Biofilm formation on visualized HR-SEM. Its anti-inflammatory measuring IL-6 release LPS-stimulated RAW 264.7 macrophages ELISA. Cell cytotoxicity normal Vero epithelial cells gas chromatography–mass spectrometry (GC-MS). Results: 5010/CBD had S. UA159, ATCC25923, clinical isolate multidrug-resistant (MDRSA CI-M) strain tested period up 17 days. 7510/CBD also activity, but overall, it less effective than over addition PEG400 copolymers significantly increased not 5010/CBD. sufficient reduce LPS-induced secretion macrophages, importantly, cytotoxic cells. found be between 1.12 9.43 µg/mL, far below dose 25 µg/mL. Conclusions: incorporation used prepare devices medical purposes where combined activities are desirable.
Language: Английский